Comment diagnostiquer une hypertension nécessitant la chlortalidone ?
Un diagnostic d'hypertension se fait par des mesures répétées de la pression artérielle.
HypertensionPression artérielle
#2
Quels tests sont nécessaires avant de prescrire la chlortalidone ?
Des tests de fonction rénale et des électrolytes sont recommandés avant la prescription.
Fonction rénaleÉlectrolytes
#3
La chlortalidone est-elle indiquée pour tous les types d'hypertension ?
Non, elle est principalement utilisée pour l'hypertension essentielle et certains œdèmes.
Hypertension essentielleŒdème
#4
Quels signes cliniques indiquent un besoin de chlortalidone ?
Une pression artérielle élevée et des signes d'œdème peuvent indiquer son utilisation.
Signes cliniquesŒdème
#5
Comment évaluer l'efficacité de la chlortalidone ?
L'efficacité se mesure par la réduction de la pression artérielle et l'amélioration des symptômes.
Efficacité thérapeutiqueSymptômes
Symptômes
5
#1
Quels symptômes peuvent justifier l'utilisation de la chlortalidone ?
Les symptômes incluent des maux de tête, des vertiges et des œdèmes aux membres.
Maux de têteVertiges
#2
La chlortalidone peut-elle provoquer des effets secondaires ?
Oui, des effets secondaires comme des déséquilibres électrolytiques peuvent survenir.
Effets secondairesDéséquilibre électrolytique
#3
Quels signes d'œdème sont traités par la chlortalidone ?
L'œdème des jambes, des chevilles et de l'abdomen sont souvent traités avec ce médicament.
ŒdèmeJambes
#4
Comment la chlortalidone affecte-t-elle la pression artérielle ?
Elle réduit la pression artérielle en augmentant l'excrétion de sodium et d'eau.
Pression artérielleExcrétion urinaire
#5
Quels symptômes indiquent une surdose de chlortalidone ?
Des symptômes comme des vertiges sévères, une déshydratation et des crampes musculaires peuvent survenir.
SurdoseDéshydratation
Prévention
5
#1
Comment prévenir l'hypertension avec la chlortalidone ?
Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est recommandé.
PréventionMode de vie sain
#2
La chlortalidone peut-elle être utilisée en prévention ?
Elle est principalement utilisée pour traiter l'hypertension, pas pour la prévention primaire.
Prévention primaireHypertension
#3
Quels changements de mode de vie complètent la chlortalidone ?
Réduire le sel, arrêter de fumer et gérer le stress sont des changements bénéfiques.
Changements de mode de vieStress
#4
La surveillance de la pression artérielle est-elle importante ?
Oui, surveiller régulièrement la pression artérielle aide à prévenir les complications.
SurveillanceComplications
#5
Quels aliments sont à éviter lors de la prise de chlortalidone ?
Il est conseillé d'éviter les aliments riches en sodium pour maximiser l'efficacité du traitement.
AlimentationSodium
Traitements
5
#1
Comment la chlortalidone est-elle administrée ?
Elle est généralement administrée par voie orale, une fois par jour, avec ou sans nourriture.
Administration oralePosologie
#2
Peut-on combiner la chlortalidone avec d'autres médicaments ?
Oui, elle est souvent combinée avec d'autres antihypertenseurs pour un meilleur contrôle.
AntihypertenseursThérapie combinée
#3
Quelle est la posologie standard de la chlortalidone ?
La posologie standard commence généralement à 12,5 mg par jour, ajustée selon la réponse.
PosologieAjustement thérapeutique
#4
Quels sont les traitements alternatifs à la chlortalidone ?
D'autres diurétiques thiazidiques ou des inhibiteurs de l'ACE peuvent être utilisés.
DiurétiquesInhibiteurs de l'ACE
#5
La chlortalidone nécessite-t-elle un suivi régulier ?
Oui, un suivi régulier de la pression artérielle et des électrolytes est essentiel.
Suivi médicalÉlectrolytes
Complications
5
#1
Quelles complications peuvent survenir avec la chlortalidone ?
Des complications comme l'hypokaliémie et la déshydratation peuvent survenir.
HypokaliémieDéshydratation
#2
Comment gérer les complications liées à la chlortalidone ?
La gestion inclut le suivi des électrolytes et l'ajustement de la posologie si nécessaire.
Gestion des complicationsÉlectrolytes
#3
La chlortalidone peut-elle causer des problèmes rénaux ?
Oui, une utilisation prolongée peut affecter la fonction rénale, nécessitant un suivi.
Problèmes rénauxFonction rénale
#4
Quels signes indiquent une complication grave ?
Des signes comme des douleurs abdominales sévères ou des changements de conscience doivent alerter.
Signes gravesDouleurs abdominales
#5
La chlortalidone augmente-t-elle le risque de diabète ?
Elle peut légèrement augmenter le risque de diabète, surtout chez les patients à risque.
DiabèteRisque
Facteurs de risque
5
#1
Quels facteurs augmentent le besoin de chlortalidone ?
L'obésité, l'âge avancé et des antécédents familiaux d'hypertension sont des facteurs de risque.
ObésitéAntécédents familiaux
#2
Le mode de vie influence-t-il l'efficacité de la chlortalidone ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent réduire son efficacité.
Mode de vieEfficacité
#3
Les personnes âgées sont-elles plus à risque ?
Oui, les personnes âgées sont souvent plus sensibles aux effets des diurétiques comme la chlortalidone.
Personnes âgéesSensibilité
#4
Le stress peut-il affecter le traitement par chlortalidone ?
Oui, le stress peut aggraver l'hypertension et diminuer l'efficacité du traitement.
StressHypertension
#5
Quels médicaments peuvent interagir avec la chlortalidone ?
Des médicaments comme les anti-inflammatoires non stéroïdiens peuvent interagir avec elle.
Interactions médicamenteusesAnti-inflammatoires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chlortalidone : Questions médicales les plus fréquentes",
"headline": "Chlortalidone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chlortalidone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2026-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chlortalidone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phtalimides",
"url": "https://questionsmedicales.fr/mesh/D010797",
"about": {
"@type": "MedicalCondition",
"name": "Phtalimides",
"code": {
"@type": "MedicalCode",
"code": "D010797",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.513.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chlortalidone",
"alternateName": "Chlorthalidone",
"code": {
"@type": "MedicalCode",
"code": "D002752",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rajiv Agarwal",
"url": "https://questionsmedicales.fr/author/Rajiv%20Agarwal",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis."
}
},
{
"@type": "Person",
"name": "Arjun D Sinha",
"url": "https://questionsmedicales.fr/author/Arjun%20D%20Sinha",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis."
}
},
{
"@type": "Person",
"name": "Wanzhu Tu",
"url": "https://questionsmedicales.fr/author/Wanzhu%20Tu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis."
}
},
{
"@type": "Person",
"name": "Stela Dineva",
"url": "https://questionsmedicales.fr/author/Stela%20Dineva",
"affiliation": {
"@type": "Organization",
"name": "Science Department, Tchaikapharma High Quality Medicines, Inc, 1 G.M. Dimitrov Blvd, 1172, Sofia, Bulgaria. s.dineva.hq@tchaikapharma.com."
}
},
{
"@type": "Person",
"name": "Katya Uzunova",
"url": "https://questionsmedicales.fr/author/Katya%20Uzunova",
"affiliation": {
"@type": "Organization",
"name": "Science Department, Tchaikapharma High Quality Medicines, Inc, 1 G.M. Dimitrov Blvd, 1172, Sofia, Bulgaria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Preferred diuretic therapy for primary hypertension: Chlorthalidone or hydrochlorothiazide?",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39051700",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/01.JAA.0000000000000057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37846572",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/HYPERTENSIONAHA.123.21932"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial.",
"datePublished": "2024-05-01",
"url": "https://questionsmedicales.fr/article/38743423",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.11081"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial.",
"datePublished": "2023-07-12",
"url": "https://questionsmedicales.fr/article/37466401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MBP.0000000000000663"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37614053",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jch.14707"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Isoindoles",
"item": "https://questionsmedicales.fr/mesh/D054833"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phtalimides",
"item": "https://questionsmedicales.fr/mesh/D010797"
},
{
"@type": "ListItem",
"position": 7,
"name": "Chlortalidone",
"item": "https://questionsmedicales.fr/mesh/D002752"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chlortalidone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chlortalidone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chlortalidone",
"description": "Comment diagnostiquer une hypertension nécessitant la chlortalidone ?\nQuels tests sont nécessaires avant de prescrire la chlortalidone ?\nLa chlortalidone est-elle indiquée pour tous les types d'hypertension ?\nQuels signes cliniques indiquent un besoin de chlortalidone ?\nComment évaluer l'efficacité de la chlortalidone ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chlortalidone",
"description": "Quels symptômes peuvent justifier l'utilisation de la chlortalidone ?\nLa chlortalidone peut-elle provoquer des effets secondaires ?\nQuels signes d'œdème sont traités par la chlortalidone ?\nComment la chlortalidone affecte-t-elle la pression artérielle ?\nQuels symptômes indiquent une surdose de chlortalidone ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chlortalidone",
"description": "Comment prévenir l'hypertension avec la chlortalidone ?\nLa chlortalidone peut-elle être utilisée en prévention ?\nQuels changements de mode de vie complètent la chlortalidone ?\nLa surveillance de la pression artérielle est-elle importante ?\nQuels aliments sont à éviter lors de la prise de chlortalidone ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chlortalidone",
"description": "Comment la chlortalidone est-elle administrée ?\nPeut-on combiner la chlortalidone avec d'autres médicaments ?\nQuelle est la posologie standard de la chlortalidone ?\nQuels sont les traitements alternatifs à la chlortalidone ?\nLa chlortalidone nécessite-t-elle un suivi régulier ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chlortalidone",
"description": "Quelles complications peuvent survenir avec la chlortalidone ?\nComment gérer les complications liées à la chlortalidone ?\nLa chlortalidone peut-elle causer des problèmes rénaux ?\nQuels signes indiquent une complication grave ?\nLa chlortalidone augmente-t-elle le risque de diabète ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chlortalidone",
"description": "Quels facteurs augmentent le besoin de chlortalidone ?\nLe mode de vie influence-t-il l'efficacité de la chlortalidone ?\nLes personnes âgées sont-elles plus à risque ?\nLe stress peut-il affecter le traitement par chlortalidone ?\nQuels médicaments peuvent interagir avec la chlortalidone ?",
"url": "https://questionsmedicales.fr/mesh/D002752#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hypertension nécessitant la chlortalidone ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic d'hypertension se fait par des mesures répétées de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant de prescrire la chlortalidone ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de fonction rénale et des électrolytes sont recommandés avant la prescription."
}
},
{
"@type": "Question",
"name": "La chlortalidone est-elle indiquée pour tous les types d'hypertension ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle est principalement utilisée pour l'hypertension essentielle et certains œdèmes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un besoin de chlortalidone ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une pression artérielle élevée et des signes d'œdème peuvent indiquer son utilisation."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité de la chlortalidone ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité se mesure par la réduction de la pression artérielle et l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent justifier l'utilisation de la chlortalidone ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des maux de tête, des vertiges et des œdèmes aux membres."
}
},
{
"@type": "Question",
"name": "La chlortalidone peut-elle provoquer des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des déséquilibres électrolytiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels signes d'œdème sont traités par la chlortalidone ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'œdème des jambes, des chevilles et de l'abdomen sont souvent traités avec ce médicament."
}
},
{
"@type": "Question",
"name": "Comment la chlortalidone affecte-t-elle la pression artérielle ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle réduit la pression artérielle en augmentant l'excrétion de sodium et d'eau."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de chlortalidone ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des vertiges sévères, une déshydratation et des crampes musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypertension avec la chlortalidone ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "La chlortalidone peut-elle être utilisée en prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est principalement utilisée pour traiter l'hypertension, pas pour la prévention primaire."
}
},
{
"@type": "Question",
"name": "Quels changements de mode de vie complètent la chlortalidone ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Réduire le sel, arrêter de fumer et gérer le stress sont des changements bénéfiques."
}
},
{
"@type": "Question",
"name": "La surveillance de la pression artérielle est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surveiller régulièrement la pression artérielle aide à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels aliments sont à éviter lors de la prise de chlortalidone ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé d'éviter les aliments riches en sodium pour maximiser l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Comment la chlortalidone est-elle administrée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par voie orale, une fois par jour, avec ou sans nourriture."
}
},
{
"@type": "Question",
"name": "Peut-on combiner la chlortalidone avec d'autres médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent combinée avec d'autres antihypertenseurs pour un meilleur contrôle."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard de la chlortalidone ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie standard commence généralement à 12,5 mg par jour, ajustée selon la réponse."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs à la chlortalidone ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres diurétiques thiazidiques ou des inhibiteurs de l'ACE peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La chlortalidone nécessite-t-elle un suivi régulier ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier de la pression artérielle et des électrolytes est essentiel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la chlortalidone ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'hypokaliémie et la déshydratation peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à la chlortalidone ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut le suivi des électrolytes et l'ajustement de la posologie si nécessaire."
}
},
{
"@type": "Question",
"name": "La chlortalidone peut-elle causer des problèmes rénaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une utilisation prolongée peut affecter la fonction rénale, nécessitant un suivi."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs abdominales sévères ou des changements de conscience doivent alerter."
}
},
{
"@type": "Question",
"name": "La chlortalidone augmente-t-elle le risque de diabète ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut légèrement augmenter le risque de diabète, surtout chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin de chlortalidone ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, l'âge avancé et des antécédents familiaux d'hypertension sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il l'efficacité de la chlortalidone ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent réduire son efficacité."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont souvent plus sensibles aux effets des diurétiques comme la chlortalidone."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter le traitement par chlortalidone ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver l'hypertension et diminuer l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec la chlortalidone ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les anti-inflammatoires non stéroïdiens peuvent interagir avec elle."
}
}
]
}
]
}
From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis.
From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis.
From the Division of Nephrology, Department of Medicine (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and the Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health (F.O., W.T.), Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center (R.A., A.D.S., A.E.C., M.B.-F., J.H.D.), and Indiana University Center for Aging Research, Regenstrief Institute (W.T.) - all in Indianapolis.
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida; Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, Florida.
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida; Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, Florida. Electronic address: julie.johnson@ufl.edu.
Division of Cardiology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande Do Sul, INCT PREVER, CPC, 5º. and Ramiro Barcelos, 2350, Porto Alegre, RS, 90035-903, Brazil. sfuchs@hcpa.edu.br.
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
From Minneapolis Veterans Affairs (VA) Health Care System, and the Department of Medicine, University of Minnesota - both in Minneapolis (A.I.); Medical Service, Memphis VA Medical Center, and the Department of Preventive Medicine, University of Tennessee Health Science Center - both in Memphis (W.C.C.); the Cooperative Studies Program Coordinating Center, VA Boston Healthcare System (S.M.L., R.A.L., P.W., C.H., A.K., M.T.B., L.D.F., R.E.F.), the Department of Biostatistics, Boston University School of Public Health (S.M.L., R.A.L.), and the Department of Medicine, Boston University School of Medicine (M.T.B., R.E.F.) - all in Boston; Pharmacy Benefits Management Services (P.A.G.) and the Office of Research and Development (G.D.H.), Department of Veterans Affairs, Washington, DC; VA Greater Los Angeles Healthcare System, and the David Geffen School of Medicine, University of California, Los Angeles - both in Los Angeles (P.A.G.); and Michael E. DeBakey VA Medical Center, and the Department of Medicine, Baylor College of Medicine - both in Houston (A.A.T.).
Because of its greater reduction of major adverse cardiovascular events (MACE), chlorthalidone is recommended over hydrochlorothiazide as the preferred diuretic for patients with primary hypertension....
Thiazide diuretics (TD) are the first-line treatment of hypertension because of its consistent benefit in lowering blood pressure and cardiovascular risk. TD is also known to cause an excess risk of d...
Accordingly, we conducted a double-blinded RCT in 60 nondiabetic hypertension patients to compare the effects of KCl versus KMgCit during chlorthalidone treatment. Each patient received chlorthalidone...
The mean age of subjects was 59±11 years (30% Black participants). Chlorthalidone alone induced a significant rise in fasting plasma glucose, and a significant fall in serum K, serum Mg, and 24-hour u...
KMgCit is superior to KCl, the common form of K supplement used in clinical practice, in preventing TD-induced hyperglycemia. This action may improve tolerability and cardiovascular safety in patients...
Patients with prior myocardial infarction (MI) or stroke have a greater risk of recurrent cardiovascular (CV) events....
To evaluate the association of chlorthalidone (CTD) vs hydrochlorothiazide (HCTZ) with CV outcomes and noncancer deaths in participants with and without prior MI or stroke....
This was a prespecified secondary analysis of the Diuretic Comparison Project (DCP), a pragmatic randomized clinical trial conducted within 72 participating Veterans Affairs health care systems from J...
Pharmacologically comparable daily dose of HCTZ or CTD and history of MI or stroke....
Outcome ascertainment was performed from randomization to the end of the study. The primary outcome consisted of a composite of stroke, MI, urgent coronary revascularization because of unstable angina...
The DCP randomized 13 523 participants to CTD or HCTZ, with a mean (SD) study duration of 2.4 (1.4) years. At baseline, median age was 72 years (IQR, 69-75 years), and 96.8% were male. Treatment effec...
Results of this secondary analysis of the DCP trial suggest that CTD may be associated with reduced major adverse CV events and noncancer deaths in patients with prior MI or stroke compared with HCTZ....
ClinicalTrials.gov Identifier: NCT02185417....
To compare the effects of chlortalidone plus amiloride and amlodipine on blood pressure (BP) variability in patients with hypertension and obstructive sleep apnea syndrome (OSA)....
A randomized, controlled, double-blind trial enrolled men and women aged 40 years or older with a diagnosis of OSA (apnea-hypopnea index 10-40 apneas/h of sleep) confirmed by overnight laboratory poly...
The study included 65 patients, with 33 assigned to the chlortalidone plus amiloride group and 32 to the amlodipine group. Participants in both groups had similar baseline characteristics. Short-term ...
In brief, our study has shown that the use of chlorthalidone in combination with amiloride and amlodipine produces comparable effects on short-term BP variability in patients with hypertension and OSA...
The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlo...
A case of hypokalemic rhabdomyolysis related to chlorthalidone use is reported SUMMARY: A 52-year-old male was admitted to the hospital for acute onset generalized weakness and was found to have sever...
Although mild hypokalemia is a known side effect of thiazide and thiazide-like diuretics, health care providers should be aware of the possibility of severe manifestations of this adverse reaction, ev...
This review addresses important issues that face practitioners today concerning the treatment of HFpEF. It points out how the accepted efficacy of HFpEF medication treatment has changed. Medications a...
Arterial hypertension is associated with increased morbidity and mortality and research in the field is highly dynamic. This summary reviews the most important clinical trials published in 2022 and ea...
Carotid artery stenosis is narrowing of the carotid arteries. Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease. It is caused by ather...
To assess the effects of pharmacological interventions for the treatment of asymptomatic carotid stenosis in preventing neurological impairment, ipsilateral major or disabling stroke, death, major ble...
We searched the Cochrane Stroke Group trials register, CENTRAL, MEDLINE, Embase, two other databases, and three trials registers from their inception to 9 August 2022. We also checked the reference li...
We included all randomised controlled trials (RCTs), irrespective of publication status and language, comparing a pharmacological intervention to placebo, no treatment, or another pharmacological inte...
We used standard Cochrane methodological procedures. Two review authors independently extracted the data and assessed the risk of bias of the trials. A third author resolved disagreements when necessa...
We included 34 RCTs with 11,571 participants. Data for meta-analysis were available from only 22 studies with 6887 participants. The mean follow-up period was 2.5 years. None of the 34 included studie...
Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbid...
Patients with acute heart failure (AHF) require intensification in the diuretic strategy. However, the optimal diuretic strategy remains unclear. In this work, we aimed to evaluate the role of urinary...
Patients with a high urinary K/Cr ratio will have a better diuretic and natriuretic response with spironolactone versus chlorthalidone....
This is a study of 44 patients with AHF-pEF with suboptimal loop diuretic response. The primary endpoint was the baseline K/Cr associated with natriuretic and diuretic effect of chlorthalidone versus ...
The median age of the study population was 85 years (82.5-88.5), and 30 (68.2%) were women. The inferential multivariate analysis suggested a greater natriuretic and diuretic effect of chlorthalidone ...
In patients with AHF-pEF and suboptimal diuretic response, diuresis and natriuresis are higher with the administration of chlorthalidone over spironolactone. These data don't support the hypothesis th...